定喘汤加减治疗痰浊阻肺型肺胀的效果分析

目的:探讨定喘汤加减治疗痰浊阻肺型肺胀的临床效果。方法:选取88例痰浊阻肺型肺胀患者,按照数字表达法分为观察组(n=44)与参考组(n=44),观察组采用定喘汤加减治疗,参考组接受常规西医治疗,比较两组治疗效果。结果:治疗后,观察组COPD评估测试呼吸问卷(CAT评分)、6min步行距离(6MWD)以及中医症候积分均显著优于参考组(P0.05);观察组肺功能各指标显著优于参考组(P0.05)。结论:定喘汤加减治疗痰浊阻肺型肺胀可改善肺功能,缓解症状,效果确切。     

桑白皮汤加减联合西药治疗痰热郁肺型肺胀疗效观察

目的观察桑白皮汤加减联合西药治疗痰热郁肺型肺胀患者的疗效。方法选取2018年3月-2019年3月深圳市宝安区人民医院收治的痰热郁肺型肺胀患者50例,采用随机数字表法分为观察组与对照组各25例。对照组患者给予常规西药治疗,观察组在对照组治疗的基础上给予桑白皮汤加减治疗,比较2组患者临床疗效。结果观察组患者总有效率为92.0%,高于对照组的68.0%(χ^2=4.500,P<0.05)。结论桑白皮汤加减联合常规西药治疗痰热郁肺型肺胀患者可获得较好的临床疗效,值得在临床上进一步推广。     

消瘀康胶囊治疗老年痰瘀阻络型脑梗死的临床疗效观察

目的消瘀康胶囊治疗痰瘀阻络型脑梗死的临床疗效观察。方法选取2015年1月至2016年1月在大连市友谊医院老年病科就诊的80例痰瘀阻络型脑梗死患者,随机分为试验组与对照组,对照组40例,按照常规西医对症治疗,试验组40例,在对照组的基础上加消瘀康胶囊。比较两组患者治疗后NIHSS评分、ADL评分。结果治疗后试验组NIHSS评分、ADL评分均优于对照组,差异有统计学意义(P<0.05)。结论在常规西医治疗的基础上采用消瘀康胶囊治疗痰瘀阻络型脑梗死,可以有效缓解神经功能缺损情况,调高生活质量,值得在临床推广。     

苓桂术甘汤合泽泻汤配合中药穴位贴敷治疗痰浊中阻型眩晕的临床观察

目的探讨苓桂术甘汤合泽泻汤配合中药穴位贴敷治疗痰浊中阻型眩晕的临床观察。方法选取我院脑病科收治的痰浊中阻型眩晕患者72例,随机分为观察组和对照组,每组36例。对照组患者采用常规西医治疗,观察组患者采用苓桂术甘汤合泽泻汤加减治疗,对两组患者治疗疗效及复发率的差异进行比较。结果观察组治疗有效率和复发率明显优于对照组,差异有统计学意义(P 0.05)。结论对痰浊中阻型眩晕患者采用苓桂术甘汤合泽泻汤配合中药穴位贴敷治疗,能够提高治疗效果,降低复发率,值得在临床推广。     

麻杏化瘀汤加减治疗肺炎喘嗽痰热闭肺型的疗效观察

目的观察麻杏化瘀汤加减治疗在小儿肺炎喘嗽痰热闭肺型的临床效果。方法选取本院2017年1月至2017年11月期间收治的小儿肺炎喘嗽痰热闭肺型患者66例,根据床号的奇偶数分成观察组和对照组各33例,对照组采取常规的西药治疗,观察组在对照组的基础上加用麻杏化瘀汤,观察两组患者的临床效果。结果观察组总有效率90.91%明显高于对照组78.79%,治疗后的积分(2.37±2.06)分明显低于对照组(6.46±3.51)分,患者主要症状消失的时间明显少于对照组,组间对比存在差异,有统计学意义(P<0.05)。结论在治疗小儿肺炎喘嗽痰热闭肺型中,麻杏化瘀汤的治疗效果显著,值得临床推广。     

宣白承气汤加减治疗痰热壅肺型重症肺炎的临床疗效观察

目的:观察分析宣白承气汤加减治疗痰热壅肺型重症肺炎的临床疗效。方法:选取2016年6月～2017年6月某院收治的60例痰热壅肺型重症肺炎患者,通过抛硬币的方式将其分为对照组和观察组各30例,对照组患者均给予常规西医治疗,观察组在其基础上实施宣白承气汤加减治疗,对比两组患者的预后。结果:观察组患者的动脉血乳酸含量、机械通气时间、CPIS评分与APACHEⅡ评分明显低于对照组(P0.05),观察组患者的ICU转出概率高于对照组(P0.05)。结论:宣白承气汤加减治疗痰热壅肺型重症肺炎,可明显提高临床疗效,改善患者临床症状,值得推广。     

麻杏石甘汤加减治疗痰热壅肺型支气管哮喘急性期疗效观察

目的观察麻杏石甘汤加减治疗急性期支气管哮喘(痰热壅肺型)的疗效。方法将痰热壅肺型支气管哮喘急性发作期患者80例随机分为两组,对照组40例,予以西医常规治疗,配合静脉用支气管扩张剂及糖皮质激素;治疗组40例,在西医常规治疗基础上,服用麻杏石甘汤加减汤药。观察两组患者的临床疗效及肺功能的变化、药费的情况。结果治疗组的总有效率优于对照组、医疗费用低于对照组。结论麻杏石甘汤加减配合西医常规治疗痰热壅肺型支气管哮喘急性发作期,疗效优于西医常规治疗加用静脉用支气管扩张剂及糖皮质激素的对照组,且大大减少西药的毒副作用,降低医疗费用。     

特定电磁波穴位照射在寒痰阻肺型慢性阻塞性肺疾病急性加重期治疗中的应用

目的 探讨特定电磁波(TDP)穴位照射在寒痰阻肺型慢性阻塞性肺疾病急性加重期治疗中的应用价值.方法 将寒痰阻肺型慢性阻塞性肺疾病急性加重期患者43例按数字表法随机分为对照组(17例)和观察组(26例).对照组予抗感染对症支持以及中药汤剂口服治疗,观察组在对照组基础上加用TDP穴位(大椎穴、左右定喘穴)照射.两组疗程均为5～10 d.观察两组的疗效、症状评分、住院时间、医疗费用及不良反应.结果 观察组总有效率为88.5％,明显高于对照组的76.5％(x2=4.54,P＜0.05).观察组治疗后症状评分、住院天数均优于对照组(均P ＜0.05),但两组医疗费用差异无统计学意义(P＜0.05).两组均未见明显的不良反应.结论 TDP穴位照射在寒痰阻肺型慢性阻塞性肺疾病急性加重期治疗中的应用,能提高疗效,具有临床推广价值.     

清金化痰汤加减治疗慢性阻塞性肺疾病急性加重期（AECOPD）痰热阻肺型的临床效果观察

目的:观察清金化痰汤加减治疗慢性阻塞性肺疾病急性加重期(AECOPD)痰热阻肺型的临床效果。方法:将我院2014年9月1日~2018年9月1日收治以AECOPD为诊断的患者75例,依照不同的治疗方法分为两组,治疗组(39例)与对照组(36例)。对照组采取西医常规治疗,治疗组采取清金化痰汤联合西医常规治疗。对比两组治疗前、后血气指标水平与中医证候积分水平及临床治疗效果。结果:治疗后两组血气与中医证候积分均有改善,治疗组优于对照组,治疗组临床治疗总有效率为97.44%明显高于对照组的83.33%(P<0.05)。结论:AECOPD痰热阻肺型采取清金化痰汤加减治疗,可明显改善中医证候水平,改善血气指标,提高临床治疗效果。     

督脉膀胱经火龙灸治疗肺肾气虚型肺胀的效果

目的探析督脉膀胱经火龙灸治疗肺肾气虚型肺胀的效果及作用机制。方法选择2019年6月至2020年6月于中山市中医院就诊的60例肺肾气虚型肺胀患者作为研究对象,采用随机数字表法分为两组,对照组(30例)予以西医常规治疗,观察组(30例)则予以督脉膀胱经火龙灸治疗,对比两组患者临床症状缓解效果、急性加重次数及6 min步行距离改善情况。结果观察组各项临床症状评分均低于对照组,差异有统计学意义(P 0.05);观察组急性加重次数低于对照组,其6 min步行距离长于对照组,差异有统计学意义(P 0.05);观察组治疗效果高于对照组,差异有统计学意义(P 0.05)。结论督脉膀胱经火龙灸治疗肺肾气虚型肺胀的效果确切,不仅可以有效缓解患者的临床症状,还能减少病症急性发作次数,增加患者6 min步行距离,值得临床应用。     

肺癌术后肺部感染原因分析及护理干预措施

目的探讨肺癌术后肺部感染的原因及护理干预措施。方法选取我院2007年6月至2008年6月手术治疗的50例老年非小细胞肺癌患者(观察组)为研究对象,结合我院实际及相关的文献,总结肺癌患者术后肺部感染的原因,并采取相应的护理干预措施,并将其与2005年6月至2006年6月手术治疗的50例老年非小细胞肺癌患者(对照组)进行比较,比较两组患者的肺部感染率、1年及3年的生存率。结果术后且观察组的肺部感染率、1年及3年的生存率显著优于对照组,P<0.05。结论有效的护理干预可减少肺癌术后感染发生率,提高患者的生存时间。     

经皮肺穿刺活检诊断肺内病变的评价

目的评价经皮肺穿刺活检对肺内病变的诊断价值。方法对52例经常规检查不能确诊的肺内病变进行经皮肺穿刺活检,对标本进行病理学检查。结果52例肺内病变确诊46例,未确诊6例。准确率88.5%。并发症中气胸5例,出血2例。结论经皮肺穿刺活检对对肺内病变诊断准确率高,并发症少,值得临床推广。     

HIV-Related Lung Disorders

Highly active antiretroviral therapy (HAART) has dramatically altered the spectrum of morbidity and mortality in HIV-infected patients. This has been attributed to improvements in the lung microenvironment leading to enhanced pulmonary immunity, either by preventing the progressive loss of immune function or by actually promoting immune restoration. However, these changes have been accompanied by the recognition of new pulmonary complications in HIV-infected subjects, especially those associated with immune reconstitution. In this review we will describe how HIV infection alters the normal pulmonary environment, highlight the effect of HAART on these perturbations, and discuss potential complications of HAART in the lung, focusing on the pulmonary immune reconstitution inflammatory syndrome.     

Diacetyl-Induced Lung Disease

Diacetyl is a diketone flavouring agent that is commonly employed for buttery taste as well as other purposes. Industrial exposure to flavouring agents, particularly diacetyl, has recently been associated with bronchiolitis obliterans, a severe respiratory illness producing fibrosis and obstruction of the small airways. This has been most commonly reported in the microwave popcorn production industry, but it has occurred elsewhere. In addition to bronchiolitis obliterans, spirometry abnormalities (fixed airflow obstruction) and respiratory symptoms have been associated with exposure. A direct effect on the respiratory epithelium with the disorganised fibrotic repair appears most likely as the underlying mechanism. Current data suggest that diacetyl is the agent responsible, although it is possible that diacetyl is simply a marker for another causative agent.     

女性肺癌

肺癌的发病率、死亡率久被认为属各肿瘤的首位,由于男性发病率以及肺癌的发病年龄较高,以往被称为"男性癌"、"老年     

Lung surfactants.

PURPOSE: The pharmacology, clinical efficacy, and cost considerations of exogenous lung surfactants are reviewed. SUMMARY: Exogenous pulmonary surfactants, along with advancements in ventilatory care, have significantly reduced the incidence of respiratory distress syndrome (RDS) and its related complications in infants. The following exogenous surfactants are approved for the prophylaxis and treatment (rescue) of neonatal RDS: beractant, a modified natural surfactant; calfactant and poractant, both natural surfactants; and colfosceril, a synthetic surfactant that is not currently available in the United States. Lucinactant, a synthetic surfactant, is under investigation and received approvable status from the Food and Drug Administration in February 2005. The surfactants are delivered directly to their site of action, and only small amounts reach the systemic circulation. Bioavailability to the distal airways and alveoli depends on the method of delivery, the stage and severity of pulmonary disease, and the properties of the particular surfactant. According to data from clinical trials, the use of exogenous surfactant therapy for rescue within the first two hours of life appears to be as efficacious as prophylaxis in most premature infants. CONCLUSION: Comparative trials of surfactants have proven the efficacy of both synthetic and natural surfactants in the prevention and treatment of RDS. However, these trials have universally demonstrated greater reduction in the immediate need for ventilator support in infants who receive natural surfactants. Natural preparations cause less pneumothorax, bronchopulmonary dysplasia, and mortality compared with synthetic preparations. Synthetic agents offer the potential advantages of an unlimited supply with consistent pharmaceutical quality and no risk of transmitting infectious disease or causing immunologic sensitization.     

肺癌患者肺切除术前的肺功能评估

肺癌患者肺切除术前的肺功能评估是用来降低围手术期和长期的发病率和死亡率.同时,内科医生必须意识到,外科手术治疗是肺癌能够治愈的最好方法.